130 related articles for article (PubMed ID: 38417442)
41. Molecular Markers of Regulatory T Cells in Cancer Immunotherapy with Special Focus on Acute Myeloid Leukemia (AML) - A Systematic Review.
Kaboli PJ; Zhang L; Xiang S; Shen J; Li M; Zhao Y; Wu X; Zhao Q; Zhang H; Lin L; Yin J; Wu Y; Wan L; Yi T; Li X; Cho CH; Li J; Xiao Z; Wen Q
Curr Med Chem; 2020; 27(28):4673-4698. PubMed ID: 31584362
[TBL] [Abstract][Full Text] [Related]
42. Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression.
Hiura T; Kagamu H; Miura S; Ishida A; Tanaka H; Tanaka J; Gejyo F; Yoshizawa H
J Immunol; 2005 Oct; 175(8):5058-66. PubMed ID: 16210609
[TBL] [Abstract][Full Text] [Related]
43. Tumors establish resistance to immunotherapy by regulating T
Marshall LA; Marubayashi S; Jorapur A; Jacobson S; Zibinsky M; Robles O; Hu DX; Jackson JJ; Pookot D; Sanchez J; Brovarney M; Wadsworth A; Chian D; Wustrow D; Kassner PD; Cutler G; Wong B; Brockstedt DG; Talay O
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243932
[TBL] [Abstract][Full Text] [Related]
44. BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors.
Itahashi K; Irie T; Yuda J; Kumagai S; Tanegashima T; Lin YT; Watanabe S; Goto Y; Suzuki J; Aokage K; Tsuboi M; Minami Y; Ishii G; Ohe Y; Ise W; Kurosaki T; Suzuki Y; Koyama S; Nishikawa H
Sci Immunol; 2022 Oct; 7(76):eabk0957. PubMed ID: 36206353
[TBL] [Abstract][Full Text] [Related]
45. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
[TBL] [Abstract][Full Text] [Related]
46. Metal-Phenolic Nanomedicines Regulate T-Cell Antitumor Function for Sono-Metabolic Cancer Therapy.
Yan J; Li W; Tian H; Li B; Yu X; Wang G; Sang W; Dai Y
ACS Nano; 2023 Aug; 17(15):14667-14677. PubMed ID: 37486249
[TBL] [Abstract][Full Text] [Related]
47. Methotrexate Restores Regulatory T Cell Function Through Demethylation of the FoxP3 Upstream Enhancer in Patients With Rheumatoid Arthritis.
Cribbs AP; Kennedy A; Penn H; Amjadi P; Green P; Read JE; Brennan F; Gregory B; Williams RO
Arthritis Rheumatol; 2015 May; 67(5):1182-92. PubMed ID: 25604080
[TBL] [Abstract][Full Text] [Related]
48. Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma.
Okuyama K; Naruse T; Yanamoto S
J Exp Clin Cancer Res; 2023 May; 42(1):114. PubMed ID: 37143088
[TBL] [Abstract][Full Text] [Related]
49. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis.
Flores-Borja F; Jury EC; Mauri C; Ehrenstein MR
Proc Natl Acad Sci U S A; 2008 Dec; 105(49):19396-401. PubMed ID: 19036923
[TBL] [Abstract][Full Text] [Related]
50. Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4.
Wing JB; Ise W; Kurosaki T; Sakaguchi S
Immunity; 2014 Dec; 41(6):1013-25. PubMed ID: 25526312
[TBL] [Abstract][Full Text] [Related]
51. Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8
Semmrich M; Marchand JB; Fend L; Rehn M; Remy C; Holmkvist P; Silvestre N; Svensson C; Kleinpeter P; Deforges J; Junghus F; Cleary KL; Bodén M; Mårtensson L; Foloppe J; Teige I; Quéméneur E; Frendéus B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058324
[TBL] [Abstract][Full Text] [Related]
52. [Immunosuppressive Environment in Tumors].
Sakai C; Nishikawa H
Gan To Kagaku Ryoho; 2018 Feb; 45(2):222-226. PubMed ID: 29483409
[TBL] [Abstract][Full Text] [Related]
53. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
Revenko A; Carnevalli LS; Sinclair C; Johnson B; Peter A; Taylor M; Hettrick L; Chapman M; Klein S; Solanki A; Gattis D; Watt A; Hughes AM; Magiera L; Kar G; Ireland L; Mele DA; Sah V; Singh M; Walton J; Mairesse M; King M; Edbrooke M; Lyne P; Barry ST; Fawell S; Goldberg FW; MacLeod AR
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387780
[TBL] [Abstract][Full Text] [Related]
54. Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression.
Yamaguchi T; Kishi A; Osaki M; Morikawa H; Prieto-Martin P; Wing K; Saito T; Sakaguchi S
Proc Natl Acad Sci U S A; 2013 Jun; 110(23):E2116-25. PubMed ID: 23690575
[TBL] [Abstract][Full Text] [Related]
55. Induction of T regulatory cells by cytotoxic T-lymphocyte antigen-2α on corneal endothelial cells.
Sugita S; Yamada Y; Horie S; Nakamura O; Ishidoh K; Yamamoto Y; Yamagami S; Mochizuki M
Invest Ophthalmol Vis Sci; 2011 Apr; 52(5):2598-605. PubMed ID: 21245393
[TBL] [Abstract][Full Text] [Related]
56. Cytotoxic-T-lymphocyte-associated antigen 4 blockade abrogates protection by regulatory T cells in a mouse model of microbially induced innate immune-driven colitis.
Watanabe K; Rao VP; Poutahidis T; Rickman BH; Ohtani M; Xu S; Rogers AB; Ge Z; Horwitz BH; Fujioka T; Erdman SE; Fox JG
Infect Immun; 2008 Dec; 76(12):5834-42. PubMed ID: 18824539
[TBL] [Abstract][Full Text] [Related]
57. Circulating and Tumor-Infiltrating Immune Checkpoint-Expressing CD8
Alsalman A; Al-Mterin MA; Murshed K; Alloush F; Al-Shouli ST; Toor SM; Elkord E
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804964
[TBL] [Abstract][Full Text] [Related]
58. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
[TBL] [Abstract][Full Text] [Related]
59. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor.
Maj T; Wang W; Crespo J; Zhang H; Wang W; Wei S; Zhao L; Vatan L; Shao I; Szeliga W; Lyssiotis C; Liu JR; Kryczek I; Zou W
Nat Immunol; 2017 Dec; 18(12):1332-1341. PubMed ID: 29083399
[TBL] [Abstract][Full Text] [Related]
60. Novel Effector Phenotype of Tim-3
Liu Z; McMichael EL; Shayan G; Li J; Chen K; Srivastava R; Kane LP; Lu B; Ferris RL
Clin Cancer Res; 2018 Sep; 24(18):4529-4538. PubMed ID: 29712685
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
